Compare AT&T Inc. (T) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs TransMedics Group Inc — how do they compare? AT&T Inc. trades at $22.24 (market cap $170.42B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: AT&T Inc. is far larger — about 62.2× TransMedics Group Inc's market cap, and AT&T Inc. pays a 4.46% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold AT&T Inc. for 118 Days and TransMedics Group Inc for 24 Days on average.
| T | TMDX | |
|---|---|---|
Market Cap | $170.42B | $2.74B |
Volume | 50,780,036 | 949,331 |
Sector | Media | Health |
52-Week High | $29.10 | $150.42 |
52-Week Low | $20.49 | $61.99 |
Typical Hold Time | 118 Days | 24 Days |
Enterprise Value | $315.74B | $3.13B |
Dividend Yield | 4.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $22.18, down 9.38% in the past 24 hours, reflecting recent market pressure despite strong fundamentals. The company shows robust profitability with a 16.94% net income margin and attractive valuation metrics including a P/E of 8.21. Recent earnings beats and a $3 billion fiber deal with Corning highlight operational strength, while technical indicators show mixed signals with overall bullish sentiment.
The stock offers value with a consensus price target of $27.50, representing 24% upside potential. Key opportunities include fiber expansion and wireless growth, balanced against risks from heavy debt load and competitive pressures. The 4% dividend yield provides income support, though investors should monitor debt management and revenue trends.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
